Article Versions Notes

Vita E, Monaca F, Mastrantoni L, Piro G, Moretti G, Sparagna I, Stefani A, Vitale A, Trovato G, Di Salvatore M, et al. COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer. Vaccines. 2025; 13(3):273. https://doi.org/10.3390/vaccines13030273

Vita, Emanuele, Federico Monaca, Luca Mastrantoni, Geny Piro, Giacomo Moretti, Ileana Sparagna, Alessio Stefani, Antonio Vitale, Giovanni Trovato, Mariantonietta Di Salvatore, and et al. 2025. "COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer" Vaccines 13, no. 3: 273. https://doi.org/10.3390/vaccines13030273

Vita, E., Monaca, F., Mastrantoni, L., Piro, G., Moretti, G., Sparagna, I., Stefani, A., Vitale, A., Trovato, G., Di Salvatore, M., Sanguinetti, M., Urbani, A., Richeldi, L., Carbone, C., Bria, E., & Tortora, G. (2025). COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer. Vaccines, 13(3), 273. https://doi.org/10.3390/vaccines13030273